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In Alzheimer’s disease, neurofibrillary tangle pathol-
ogy appears to spread along neuronal connections,
proposed to be mediated by the release and uptake
of abnormal, disease-specific forms of microtubule-
binding protein tau MAPT. It is currently unclear
whether transfer of tau between neurons is a toxic
gain-of-function process in dementia or reflects a
constitutive biological process. We report two entry
mechanisms for monomeric tau to human neurons:
a rapid dynamin-dependent phase typical of endocy-
tosis and a second, slower actin-dependent phase of
macropinocytosis. Aggregated tau entry is indepen-
dent of actin polymerization and largely dynamin
dependent, consistent with endocytosis and distinct
from macropinocytosis, the major route for aggre-
gated tau entry reported for non-neuronal cells.
Anti-tau antibodies abrogate monomeric tau entry
into neurons, but less efficiently in the case of aggre-
gated tau, where internalized tau carries antibody
with it into neurons. These data suggest that tau en-
try to human neurons is a physiological process and
not a disease-specific phenomenon.
INTRODUCTION
The microtubule-associated protein tau (MAPT) is involved
in the pathogenesis of several forms of dementia, including
Alzheimer’s disease (AD) and frontotemporal dementia (FTD).
Mutations in the MAPT gene are causal for some familial forms
of FTD (Ghetti et al., 2015), and the formation of intracellular,
hyperphoshorylated aggregates of tau (neurofibrillary tangles
[NFTs]) is a common pathological feature in AD, FTD, and
other dementias (Grundke-Iqbal et al., 1986; Kosik et al.,
1986). Disease progression, and clinical severity of symptoms,
is associated with a predictable spatial and temporal order
of appearance of NFTs in different forebrain regions (Braak
and Braak, 1991). This has led to the proposal that these3612 Cell Reports 22, 3612–3624, March 27, 2018 ª 2018 The Autho
This is an open access article under the CC BY license (http://creativediseases actively spread from diseased to healthy neurons in
a spatial and temporal progression, mediated by extracellular,
abnormal, disease-associated forms of tau (Iba et al., 2013;
Liu et al., 2012).
It is not currently known if neuronal release and internalization
of extracellular tau are disease-specific phenomena that spread
disease through the CNS or are fundamental physiological pro-
cesses. In vivo, tau protein is present in interstitial fluid of
the CNS and passes into cerebrospinal fluid (CSF), where it is
found in concentrations on the order of 15 pM (Blennow et al.,
1995; Olsson et al., 2005). Mice transgenic for human tau have
10-fold higher concentrations of tau in brain interstitial fluid
than in CSF, which would suggest that the extracellular concen-
trations of tau in the human brain are in the high picomolar-low
nanomolar range (Yamada et al., 2011). There is strong evidence
for the regulated release of non-pathogenic forms of tau from
healthy neurons and of tau entry into neurons and non-neuronal
cells (Bright et al., 2015; Chai et al., 2012; Kanmert et al., 2015;
Wang et al., 2017). There have been conflicting reports about
the ability of extracellular monomeric tau to enter cells, whereas
aggregated or fibrillar tau has been clearly shown to efficiently
enter neurons and other cell types (Frost et al., 2009; Kfoury
et al., 2012; Wu et al., 2013).
We used human stem cell-derived neurons to address open
questions about the efficiency with which tau enters human neu-
rons, which forms (monomeric and aggregated) of tau enter neu-
rons, and the routes by which they do so. We found that both
forms of tau are efficiently taken up by human neurons, by over-
lapping but distinct mechanisms, consistent with regulated
endocytosis. Monomeric tau enters neurons by two different
routes and is actively trafficked within the neuron. Tau entry
into neurons can be attenuated by antibody binding, however,
extracellular tau-antibody complexes are internalized into
intracellular compartments.
RESULTS
Rapid and Efficient Entry of Extracellular Monomeric
and Aggregated Tau into Human Neurons
We first analyzed the ability of monomeric and aggregated
tau (P301S) proteins to enter human cortical neurons from thers.
commons.org/licenses/by/4.0/).
Figure 1. Human Neurons Efficiently Inter-
nalize Extracellular Monomeric and Aggre-
gated Tau
(A) Neuronal uptake of extracellular monomeric or
aggregated forms of tau P301S protein conjugated
to an amide-reactive fluorophore (green in merge;
tau-Dylight) after 2 hr of incubation or without tau
protein (no tau added). Fixed human iPSC-derived
neurons (70 days after induction) were co-stained
with DAPI (nuclear DNA; blue in merge) and MAP2
(neuronal dendrites and cell bodies; red in merge).
Confocal microscopy representative images are
shown. Scale bar, 50 mm.
(B) Analysis of the proportion of tau-containing
neurons following the addition of extracellular tau.
Human iPSC-derived neurons (63 days after induc-
tion) were incubated with monomeric or aggregated
tau-Dylight protein for 4 hr before dissociation
into single cells and analysis by flow cytometry.
Scatterplots of DAPI/tau-Dylight double-labeled
neurons were gated by intensity of DAPI fluores-
cence and subsequently by tau-Dylight fluores-
cence. Neurons without tau incubation (no tau
added) were used to establish the threshold level for
detection of tau-Dylight fluorescence.
(C) Percentage of DAPI/tau-Dylight double-positive
iPSC-derived cells (total count of >7 3 103 cells)
following incubation with either monomeric or
aggregated tau. Error bars indicate SEM (n = 6). See
also Figures S1–S4.extracellular milieu. We used the tau P301S variant, an auto-
somal dominant mutation that causes early onset FTD with
high penetrance (Bugiani et al., 1999; Guo et al., 2017). Focusing
on P301S tau enabled us to study the transmission of a disease-
relevant, aggregation-prone variant that differs from normal tau
by a single amino acid, comparing monomeric and aggregated
forms directly.
To do so, purified recombinant monomeric (native) or heparin-
aggregated tau proteins conjugated to an amide reactive fluoro-
phore (tau-Dylight 488 NHS ester) were incubated with induced
pluripotent stem cell (iPSC)-derived cerebral cortex excitatory
neurons for 2 hr (Figure 1A; Figures S1 and S2). After extensive
washing, monomeric and aggregated tau-Dylight were both de-
tected within cells expressing the neuron-specific microtubule-
associated proteinMAP2, confirming that both forms of tau enter
neurons. Tau-Dylight was found predominantly within the so-
matic compartment of neurons (Figure 1A). After a 4-hr incuba-
tion with extracellular tau, flow cytometry analysis (Figures 1B
and 1C) revealed that 83% and 73% of dissociated cells
contained monomeric or aggregated tau-Dylight, respectively,
demonstrating that extracellular tau efficiently enters human
neurons in culture. Internalization of monomeric tau (P301S)
and wild-type tau was comparable and concentration depen-
dent (Figure S3A), confirming that the P301S mutation doesCell Rnot confer the ability to efficiently enter
neurons, nor is this form of tau likely
to aggregate in extracellular media during
the 3- to 4-hr incubation period. Tau deriv-atives and oligomeric states had no significant cytotoxic effect
over the course of the assays (3–4 hr; Figures S3B and S3C).
Concentration-Dependent Entry of Tau into Neurons via
Low-pH Transport Vesicles
Live imaging of human cortical neurons was used to investigate
the underlying mechanisms of neuronal entry of monomeric and
aggregated tau. To do so, we prepared purified recombinant tau
P301S protein conjugated to a maleimide-reactive pH-sensitive
dye (tau-pHrodo Red), a reporter detectable in low-pH environ-
ments, including late endosomes and lysosomes. Incubation of
tau-pHrodo with human neurons at a range of concentrations
from 2.5 to 25 nM (0.12–1.2 mg.mL1, diluted in culture medium)
showed that tau entry to neurons is rapid, as visualized by live
imaging. As we found with the amine-labeled tau-Dylight that
conjugates the dye to lysine residues, maleimide-labeled tau-
pHrodo (which conjugates to cysteine residues) showed con-
centration-dependent internalization, indicating that the position
and chemical nature of each dye does not impact uptake.
To confirm that the dyes do not enable tau to enter neurons,
we added FLAG-tagged tau with no fluorescent labels to human
neurons, and we purified FLAG-tagged, intracellular tau from
neurons at 24-hr intervals over a 4-day period using anti-FLAG
immunoprecipitation. We found that FLAG-tagged tau enterseports 22, 3612–3624, March 27, 2018 3613
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neurons efficiently and that internalized tau persists at detect-
able levels within neurons for at least 4 days (Figure S4A). 3R
and 4R splice isoforms of tau have one and two cysteines,
respectively, enabling the production of forms of tau containing
one or two pHrodo labels per tau molecule. We found that these
two forms of pHrodo-tau differed approximately 2-fold in their
fluorescent signal when added at the same concentration to hu-
man neurons, demonstrating the overall efficiency of protein la-
beling and the scaling of the fluorescent signal to intracellular tau
entry (Figure S4B).
Intracellular fluorescent punctae were observed within the first
10 min of exposure of neurons to monomeric tau-pHrodo (Fig-
ure 2A; Video S1). Tau-pHrodo-positive structures increased in
size and intensity over the 4-hr course of the assay. These struc-
tures were present within neurites and accumulated in the cell
bodies of neurons. In the presence of 15 and 25 nM monomeric
tau-pHrodo, the number of tau-pHrodo-positive objects ap-
proached a plateau (>90% of final measurement) after approxi-
mately 1 hr (Figure 2C).
Internalization of aggregated tau-pHrodo (Figure 2D) was
also found to be concentration dependent (Figure 2E). However,
unlike monomeric tau-pHrodo, the number of detectable tau-
pHrodo-positive objects (Figure 2F) did not increase immediately
but displayed a lag for the first hour (Figure 2E). These kinetics of
aggregated tau-pHrodo entry are similar to that of both lower
concentrations of monomeric tau (2.5 nM) and of low-molecular
weight (10-kDa) dextran-pHrodo (same molarity as monomeric
tau samples; Figures S5A–S5C). Direct quantitative comparison
of the amount of monomeric and aggregated tau-pHrodo
entering at different concentrations is not possible under these
experimental conditions, as the mixed nature of aggregated
tau fibrils prevents us from establishing molarity accurately.
We confirmed that heparin within the aggregated tau prepara-
tions did not contribute to tau entry into neurons, finding that
uptake of both monomeric and aggregated tau was unaffected
in the presence of heparin (Figures S4C and S4D).
Monomeric Tau and Aggregated Tau Appear in Early
Endosomes and in Lysosomes
To establish the route of vesicular internalization of monomeric
and aggregated tau, we analyzed the appearance of tau-Dylight
in endosomal or lysosomal compartments in iPSC-derived hu-
man neurons. Monomeric or aggregated tau-Dylight (total pro-
tein concentration 10 mg.mL1, 250 nM) was incubated with
neurons for up to 6 hr, then extensively washed to remove extra-
cellular protein and fixed. Co-localization of tau with endosomesFigure 2. Human Neurons Internalize Extracellular Tau via Low-pH Int
(A) Time-lapse (0- to 4-hr) images showing concentration-dependent uptake of ex
[2.5, 15, or 25 nM]; inverse relationship between fluorescence and pH) into iPSC
merge) and pH-sensitive fluorescent signal (pHrodo; red in merge) were capture
independent measurements were taken from three technical replicates at 10-min
(B and C) Following the extracellular addition of 2.5, 15, or 25 nM tau-pHrodo, th
positive objects (C) were measured over 4 hr. Intensity (a.u.) and object measure
indicate SD.
(D–F) Concentration-dependent uptake of 0.12, 0.7, or 1.2 mg.mL1 extracellu
respectively) into human neurons using the same experimental conditions and p
number of pHrodo positive objects (F) were measured as in (B and C). See also(early endosomal antigen-1 [EEA1] immunofluorescence; Fig-
ure 3A) or late endosomes and lysosomes (LAMP1 immunofluo-
rescence; Figure 3B) was analyzed by confocal microscopy.
In agreement with the monomeric tau-pHrodo experiments,
monomeric tau-Dylight was rapidly taken up into neurons (Fig-
ure 3C). In contrast, IgG-Dylight showed little detectable entry
into neurons throughout the time course (data not shown).
As early as 1 hr after the addition of extracellular tau, mono-
meric and aggregated tau-Dylight were co-localized in EEA1+
early endosomes. Monomeric and aggregated tau-Dylight were
alsodetected inLAMP1+ lateendosomesand lysosomes, consis-
tent with endocytosed proteins first reaching early endosomes,
before late endosomes and lysosomes.
Live imaging (Figure 3G; Video S2) of neurons incubated with
aggregated tau-pHrodo (4 hr, 0.7 mg.mL1) enabled the longer-
term tracking of tau-pHrodo-containing vesicles within neurons.
Tau-containing vesicles were rapidly (>10 mm/s) transported in
both antero- and retrograde directions along neurites, and they
could rapidly reverse direction of transport (Figure 3G). Thus,
monomeric and aggregated tau both efficiently enter neurons
via the endosome/lysosome system, and they are actively traf-
ficked within vesicles over long distances within neurons over
several hours.
Differential Effects of Dynamin Inhibition on
Endocytosis of Monomeric and Aggregated Tau
As extracellular monomeric and aggregated tau utilize endoso-
mal pathways to enter neurons but display different kinetics of
uptake, we examined whether the underlying internalization
mechanisms of tau protein species differ. First, we tested the
sensitivity of monomeric and aggregated tau internalization to
the small molecule inhibitor Dynasore (Figure 4), an inhibitor of
the GTPase dynamin, which is required for numerous membrane
fission events, including clathrin-mediated endocytosis (Preta
et al., 2015). Following 30-min pre-incubation with 100 mM
Dynasore or vehicle control, entry of extracellular monomeric
(25 nM) or aggregated tau-pHrodo (1.2 mg.mL1) was assessed
by live imaging over 4 hr.
The amount of monomeric tau entering neurons, as measured
by total fluorescent intensity of intracellular monomeric tau-
pHrodo vesicles, was significantly reduced by dynamin inhibi-
tion, as shown at 1 and 3 hr after the addition of extracellular
tau (Figure 4B). This was also reflected in the significant
reduction in the number of tau-pHrodo-positive objects at 1 hr
(compared with vehicle control; Figure 4C). The kinetics of
appearance of intracellular monomeric tau-pHrodo objectsracellular Vesicles in a Concentration-Dependent Manner
tracellular monomeric tau P301S conjugated to a pH-sensitive dye (tau-pHrodo
-derived human neurons (75 days after induction). Bright-field (gray scale in
d using automated imaging on the Opera Phenix platform (PerkinElmer). Nine
intervals. Scale bar, 100 mm.
e sum intensity of the pHrodo-positive objects (B) and the number of pHrodo-
ments are displayed over time and at a 3-hr time point (dashed line); error bars
lar aggregated tau-pHrodo (equivalent to 2.5, 15, or 25 nM monomeric tau,
arameters as in (A). Sum intensity of the pHrodo positive objects (E) and the
Figure S5.
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Figure 3. Internalized Monomeric and Aggregated Tau Are Traf-
ficked in Early Endosomes and Lysosomes
(A) Images of human iPSC-derived neurons (82 days after induction) following
incubation with 100 nMmonomeric tau P301S-Dylight (shown in cyan) for 0, 1,
or 6 hr. Neurons washed with PBS were immunostained for EEA1 (early en-
dosomes; left panel) or LAMP-1 (lysosomes; right panel) and nuclei were
counterstained with DAPI (blue). Co-localization of tau-Dylight with endo-
somes and lysosomes appears white in images and is indicated by arrows;
insets show magnifications of the area indicated in the main image. Scale bar,
50 mm.
3616 Cell Reports 22, 3612–3624, March 27, 2018changed in the presence of dynamin inhibitor, displaying an
initial lag in entry. However, the number of tau-pHrodo objects
then reached the same level as vehicle-treated controls by
3 hr, although not the same total intensity (Figure 4C), which
may reflect a reduction in endosome/lysosome acidification
in the presence of Dynasore. This suggests that there are two
distinct mechanisms of entry of monomeric tau into human
neurons, one of which is rapid and dynamin dependent and
the other being slower and independent of dynamin.
The effect of dynamin inhibition on the entry of aggregated tau
was more pronounced than on monomeric tau (Figures 4D–4F).
The total fluorescent intensity of intracellular aggregated tau-
pHrodo was consistently reduced by more than 70% at 1 and
3 hr after tau addition (Figure 4E), and the number of tau-
pHrodo-positive objects was reduced by 95% (Figure 4F). These
data indicate that, at the concentrations studied, aggregated tau
enters neurons almost entirely via endocytosis.
Perturbation of Actin Dynamics Confirms that
Monomeric Tau and Aggregated Tau Have Overlapping
but Different Routes to Enter Neurons
To explore further whether monomeric and aggregated tau
enter neurons via different mechanisms, we studied the role of
actin polymerization in this process (Figure 5). Inhibition of actin
polymerization with Cytochalasin D disrupts several clathrin-
independent endocytic processes, including bulk endocytosis/
macropinocytosis (Mooren et al., 2012). Disruption of actin poly-
merization has previously been shown to inhibit entry of fibrils
formed of the tau repeat domain (Holmes et al., 2013). Therefore,
neuronal entry of tau-pHrodo was measured over 3 hr in the
presence of extracellular monomeric (25 nM) or aggregated
(1.2 mg.mL1) tau-pHrodo, following a 30-min pre-incubation
with 0.1 or 1 mM Cytochalasin D or vehicle control.
Entry of monomeric tau was markedly reduced in the presence
of 1 mM Cytochalasin D, as reflected in the 95% reduction in the
number of monomeric tau-pHrodo-positive objects after 3-hr
incubation in the presence of 1 mM Cytochalasin D (Figure 5C). In
contrast, disruption of actin polymerization with Cytochalasin D
had little effect on the entry of aggregated tau (total fluorescent
intensity and number of objects; Figures 5D–5F; Figure S5).
Live imaging of tau entry with pHrodo-tau may not detect
intracellular pools of tau that enter via a different mechanism,
avoiding low-pH environments. Additionally the pharmacolog-
ical treatments may also affect the acidification of intracellular(B and C) Quantification of tau-Dylight and EEA1 (B) or LAMP1 (C) double-
positive objects per nucleus over time. 25 independent z stacks were analyzed
per condition and time point; error bars indicate SD.
(D) Analysis of co-localization of internalized aggregated tau-Dylight
(4.8 mg.mL1, 100 nM equivalent of monomeric) with endosomes and lyso-
somes over 6 hr, using the same experimental conditions and parameters as (A).
(E and F) Quantification of aggregated tau-Dylight and (E) EEA1- or (F) LAMP1-
double-positive objects per nucleus over time.
(G) Live tau-pHrodo imaging demonstrates the movement of low-pH vesicular
structures in neurons. Representative images show neurons (80 days after
induction) after 4-hr incubation with 1.2 mg.mL1 aggregated tau-pHrodo
imaged at 1-s intervals. Yellow arrows indicate intracellular mobile tau-
pHrodo-positive objects and red arrows indicate the direction of movement.
See also Videos S1 and S2.
Figure 4. Monomeric and Aggregated Tau
Enter Neurons via Different Mechanisms
(A) Time-lapse (0- to 4-hr) imaging of human
neuronal uptake of extracellular monomeric and
aggregated tau P301S-pHrodo following dynamin
inhibition. Neurons (75 days after induction) were
pre-incubated with 100 mM Dynasore (dynamin
inhibitor) or vehicle control (1% [v/v] DMSO) for
30min prior to exposure to 1.2 mg.mL1 extracellular
tau-pHrodo and Dynasore or vehicle. Bright-field
(gray scale in merge) and pH-sensitive fluorescent
signal (pHrodo; red in merge) were captured using
automated imaging on the Opera Phenix platform
(PerkinElmer). Nine independent measurements
were taken from three technical replicates at 10-min
intervals. Scale bar, 100 mm.
(B and C) Sum intensity of the pHrodo-positive
objects (B) and number of pHrodo-positive objects
(C) were measured over 4 hr. Intensity and object
measurements are displayed over time and at 1- and
3-hr time points (dashed lines). Error bars indicate
SD. Significance was determined using unpaired
t tests (n = 3; *p < 0.05, **p < 0.005, ***p < 0.0005,
and ****p < 0.0001).
(D–F) Effect of dynamin inhibition on internalization
and acidification of extracellular aggregated tau-
pHrodo into intraneuronal compartments using the
same experimental conditions and parameters as in
(A). Sum intensity of the pHrodo positive objects (E)
and the number of pHrodo positive objects (F) were
measuredas in (BandC).SeealsoFiguresS5andS6.vesicles, which could affect the pHrodo signal. To control for
this, we performed tau-Dylight internalization assays in the pres-
ence of 100 mM Dynasore or 1 mM Cytochalasin D (Figure S6),
with 3 hr of incubation with 100 mM extracellular monomeric or
aggregated tau. Compared with the live-imaging studies, rela-
tively high concentrations of aggregated tau were used to inves-
tigate whether the dynamin-dependence and actin-indepen-
dence of neuronal entry seen by live imaging were related to
the lower molarity of aggregated versus monomeric tau used
for those experiments. These independent assays confirmed
the same differential effects of the two inhibitors observed by
live imaging of pHrodo-tau: at the 3-hr assay point, dynamin in-
hibition had no effect on the number of monomeric tau-Dylight-
positive punctae within neurons, whereas inhibition of actin poly-
merization reduced the amount of intracellular tau by over half
(Figure S6). Conversely, dynamin inhibition significantly reduced
the entry of aggregated tau, with no significant effects of Cyto-
chalasin D (Figure S6) at this relatively high molar concentrationCell Rof aggregated tau. The different pharmaco-
logical treatments and control recombinant
proteins had no significant cytotoxic ef-
fect over the course of the assays (3–4 hr;
Figure S5).
Anti-tau Antibodies Slow Neuronal
Internalization of Extracellular Tau
It is not currently known if tau entry into
neurons requires specific domains of tau,specific cell surface-binding proteins, or receptors. Antibodies
that recognize extracellular tau are a potential therapeutic
strategy for slowing disease progression through the CNS by
inhibiting tau entry into neurons (Congdon et al., 2016; Gu and
Sigurdsson, 2011). Complex formation between specific anti-
bodies and tau results in an increase in molecular size and
may alter or mask uptake recognition sites on tau, thus prevent-
ing neuronal entry of tau.
We analyzed the ability of a polyclonal antibody to the C-termi-
nal half of tau to reduce tau protein entry into human cortical
neurons. The anti-tau antibody or control IgGs (250 nM) were
incubated with either monomeric (25 nM) or aggregated
(1.2 mg.mL1) tau-pHrodo at approximately 10-fold excess of
antibody for 30 min. Tau-antibody mixtures were then added
to iPSC-derived human neurons, and tau entry was assessed
by live imaging of fluorescent intracellular tau-pHrodo (Figure 6).
Pre-incubation with the polyclonal (anti-taupAb) tau antibody
reduced the amount of monomeric tau that entered neurons,eports 22, 3612–3624, March 27, 2018 3617
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as assessed by the number of monomeric tau-pHrodo-contain-
ing vesicles (Figure 6B; Figure S7). The kinetics of monomeric
tau entry were affected by the presence of tau-specific anti-
bodies, such that an initial lag in the appearance of defined
tau-pHrodo-positive objects was observed (Figure 6B).
Tau antibodies also reduced entry of aggregated tau uptake
into human neurons (Figure 6C). In the presence of anti-taupAb,
the number of aggregated tau-pHrodo vesicles was reduced
by more than half (Figure 6D; Figure S7). IgG antibodies that
do not recognize tau appear to have some minor effects on
monomeric and aggregated tau entry, which may be due to
competition between tau and IgG for endocytosis.
The effect of tau antibodies on the entry of tau-Dylight into
neurons was also tested (Figure S7), using the same concentra-
tions and pre-incubation time as the tau-pHrodo assays.
After 3 hr of incubation with antibodies and extracellular mono-
meric or aggregated tau, neurons were washed, fixed, and the
number of intracellular tau-Dylight punctae was quantified.
These independent assays confirmed that tau-specific anti-
bodies significantly reduced the amount of tau-Dylight entering
neurons (Figure S7).
Entry of Aggregated Tau-Antibody Complexes into
Neurons
Although tau was pre-incubated with a large molar excess of an-
tibodies (103) before addition to neurons, some monomeric and
aggregated tau still entered neurons. This raised the question of
whether the tau that entered neurons under these conditions did
so in a complex with antibodies or if a fraction of antibody-free
tau was available for neuronal entry. To distinguish between
these possibilities, we performed additional assays using pre-
formed aggregated tau-Dylight-antibody complexes. After 3 hr
of incubation, antibodies were detected in the fixed neurons
with a secondary antibody specific to the host species (anti-
rabbit polyclonal; Figure 7) and also imaged for tau-Dylight.
Intraneuronal punctae positive for both tau-Dylight and tau-
specific antibodies were detected after binding of extracellular
tau with anti-taupAb, demonstrating that tau-antibody complexes
do enter human neurons. No intraneuronal tau-antibody com-
plexes were detected when aggregated tau was incubated
with IgG control.
DISCUSSION
We find here that monomeric wild-type and FTD tau (P301S)
and aggregated tau (P301S) all efficiently enter human neurons,Figure 5. Perturbation of Actin Polymerization Confirms that Monom
Mechanisms
(A) Time-lapse (0- to 3-hr) imaging of human neuronal uptake of extracellular m
polymerization. Neurons (65 days after induction) were pre-incubated with 0.1 o
exposure to 1.2 mg.mL1 extracellular tau-pHrodo and Cytochalasin D or vehicle.
red in merge) were captured using automated imaging on the Opera Phenix pla
technical replicates at 10-min intervals. Scale bar, 100 mm.
(B and C) Sum intensity of pHrodo-positive objects (B) and number of pHrodo-
measurements are displayed over time and at 1- and 3-hr time points (dashed lin
(D–F) Effect of inhibition of actin polymerization on internalization of extracellular a
same experimental conditions and parameters as in (A). Sum intensity of the pH
measured as in (B and C). See also Figures S5 and S6.arguing that tau entry to neurons is a constitutive biological pro-
cess and not a disease-specific phenomenon. Both monomeric
and aggregated species of tau enter neurons via a dynamin-
dependent process, with monomeric tau also entering neurons
through a second, slower pathway dependent on actin poly-
merization. Monomeric and aggregated tau access neurons via
the lysosome/endosome system. Internalized tau persists within
neurons for a minimum of 4 days, and a fraction of tau is dynam-
ically transported long distances in neurons within low-pH vesi-
cles for lengthy periods. The amount of monomeric and aggre-
gated tau entering neurons is reduced by polyclonal anti-tau
antibodies. However, a notable amount of tau enters neurons
complexed with antibodies, even in the presence of a 10-fold
molar excess of antibodies. While antibody binding may affect
intracellular trafficking of tau and the final destination of tau
within the neuron (McEwan et al., 2017), these data demonstrate
that simple binding of tau by antibodies is not sufficient to
prevent neuronal entry when tau is presented in solution to the
neuron.
In contrast to earlier reports fromHEK cells and primary rodent
neurons (Frost et al., 2009; Holmes et al., 2013; Wu et al., 2013),
full-length monomeric tau efficiently and rapidly enters healthy
human neurons, and it does so as efficiently as aggregated
tau. We find that there are two mechanisms of entry of mono-
meric tau into neurons: a rapid early phase that can be blocked
by dynamin inhibition; and a second, slower phase that is actin
dependent. These two mechanisms suggest that monomeric
tau enters neurons via a rapid saturable dynamin-mediated
endocytic mechanism and also by bulk endocytosis (Loebrich,
2014). In contrast to monomeric tau, aggregated tau entry
is independent of actin polymerization and largely dynamin
dependent, consistent with classic endocytosis. The lack of
actin dependence of aggregated tau entry into neurons suggests
that it does not enter human neurons via macropinocytosis, as
has been reported in non-neuronal cells (Holmes et al., 2013).
Rapid endocytosis of both monomeric and aggregated tau
would typically require one or more specific receptors or carrier
molecules, the identities of which are currently unknown. Spe-
cific surface receptors have been identified for fibrils of alpha-
synuclein (Mao et al., 2016), and that receptor shows specificity
for aggregated synuclein over the monomeric form, which may
suggest that, although both species of tau enter neurons via
endocytosis, they may do so through distinct surface receptors.
As a largely disordered protein, the most obvious candidate
region for recognition for cellular entry of monomeric tau is the
highly ordered microtubule-binding region of tau (Butner anderic and Aggregated Tau Enter Neurons through Distinct Uptake
onomeric and aggregated tau P301S-pHrodo following the inhibition of actin
r 1 mM Cytochalasin D or vehicle control (1% [v/v] DMSO) for 30 min prior to
Bright-field (gray scale in merge) and pH-sensitive fluorescent signal (pHrodo;
tform (PerkinElmer). Eight independent measurements were taken from three
positive objects (C) were measured over 3.3 hr. Intensity and object number
es). Error bars indicate SD (n = 3; **p < 0.01, Dunnet’s multiple comparisons).
ggregated tau-pHrodo into low-pH compartments in human neurons using the
rodo positive objects (E) and the number of pHrodo positive objects (F) were
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Figure 7. Aggregated Tau-Antibody Complexes Are Endocytosed by Human Neurons
Confocal microscope images of neuronal uptake of extracellular aggregated tau P301S-Dylight-antibody complexes. Pre-formed (30-min incubation) aggregated
tau-Dylight-antibody (anti-taupAb or an IgG control) complexes were added to iPSC-derived neurons (71 days after induction). After 3 hr of incubation, neurons
were washed, fixed, and co-stained with antibody specific to the pre-incubation antibodies (donkey anti-mouse IgG Alexa 594 or donkey anti-rabbit IgG Alexa
594) and nuclear (DAPI; blue in merge) and dendritic markers (MAP2; white in merge). Scale bar, 100 mm. See also Figure S7.Kirschner, 1991). Detailed understanding of the different paths of
entry for monomeric and aggregated tau, and the regions of tau
required for uptake, will be useful for investigating the potential
for specifically preventing interneuronal transfer of aggregated
tau without interfering with the transfer of non-pathogenic forms.
In addition to the importance of these questions for under-
standing mechanisms of dementia pathogenesis, they also
have implications for immunotherapy strategies that target
extracellular tau as disease-modifying treatments for dementia.
Tau immunotherapy strategies have been shown to alter tau
transmission in mouse models (Congdon et al., 2016; Gu and
Sigurdsson, 2011). Proposed mechanisms for tau immuno-
therapies are epitope, affinity, conformation, and aggregate
size dependent. Studies of specific tau immunotherapies have
demonstrated that either extracellular (Yanamandra et al.,
2013) or intracellular (Gu et al., 2013; Nicholls et al., 2017) tau
can be targeted. Antibodies are thought to halt the progression
of disease by binding to tau aggregates, triggering their uptake
and clearance via either endosomal or proteasome pathways
(Chai et al., 2011; Gu et al., 2013; Mallery et al., 2010). Fluid
phase (Funk et al., 2015) and Fc receptor-mediated (CongdonFigure 6. Anti-tau Antibody Attenuates Neuronal Uptake of Extracellul
(A–C) Time-lapse (0- to 4-hr) imaging of the effects of anti-tau polyclonal antib
neurons. Monomeric tau-pHrodo (25 nM) was pre-incubated with culture medium
antibodies, or vehicle control (PBS) for 30 min. Tau-antibody incubations were ad
field (gray scale in merge) and pH-sensitive fluorescent signal (pHrodo; red in m
(PerkinElmer). Eight independent measurements were taken from three technica
(B and C) Intensity (B) and number (C) of pHrodo-positive objects measured over 4
vehicle, anti-tau polyclonal antibody, or two different control IgG antibodies. Inten
(dashed line). Error bars indicate SD and significance was determined using one-
comparisons).
(D–F) Effect of tau antibody on the internalization of extracellular aggregated ta
analysis parameters as (A). Sum intensity of the pHrodo positive objects (E) andet al., 2016) endocytosis have both been implicated in the uptake
of antibody-tau complexes into neurons and microglia. The con-
sequences for the neuron of uptake of antibody-antigen com-
plexes are not clear, and they would depend in part on whether
those complexes are degraded or accumulate in the endosome/
lysosome or transit to the cytoplasm, where they could be
detected by the cytosolic Fc receptor TRIM21 and targeted for
degradation (McEwan et al., 2017).
The data presented here from in vitro experiments suggest
that entry of tau into human neurons is an efficient physiological
process rather than a disease-specific gain of function. Most
current immunotherapy approaches targeting extracellular tau
do not distinguish between pathogenic forms of tau that are
thought to propagate disease and the forms of extracellular tau
that are found in the healthy brain (Bright et al., 2015). Disruption
of interneuronal transfer of non-pathogenic tau may have delete-
rious effects, if that transfer has a biological function, which is
currently not known. Current clinical trials of anti-tau antibodies
have not so far reported deleterious effects relating to the disrup-
tion of interneuronal transfer of non-pathogenic tau, and the field
awaits the outcomes of longer-term trials. Furthermore,ar Tau
ody on the internalization of extracellular monomeric tau-pHrodo by human
containing 250 nM polyclonal anti-tau (anti-taupAb), IgG control (IgG1; IgG2)
ded to iPSC-derived human neuronal cultures (75 days after induction). Bright-
erge) were captured using automated imaging on the Opera Phenix platform
l replicates at 10-min intervals. Scale bar, 100 mm.
hr after the addition of extracellular monomeric tau-pHrodo in the presence of
sity and object measurements are displayed over time and at a 3-hr time point
way ANOVA (n = 3; *p < 0.05, **p < 0.005, and ****p < 0.0001, Dunnet’s multiple
u-pHrodo into human neurons using the same experimental conditions and
the number of pHrodo positive objects (D) were measured as in (B and C).
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therapeutics that are not selective for extracellular pathogenic
forms of tau may not achieve appropriate levels of target
engagement in the presence of concentrations of non-patho-
genic tau that are higher than those of pathogenic tau. Therefore,
it will be important to ascertain the biological functions of
neuronal release and internalization of tau. It will also be essential
to identify which extracellular tau forms are truly pathogenic to
facilitate the rational design of therapies that target interneuronal
transfer of tau to prevent disease progression.
EXPERIMENTAL PROCEDURES
Production and Characterization of Human iPSC-Derived Cerebral
Cortex Neurons
Directed differentiation of human embryonic stem cells (hESCs) and iPSCs to
cerebral cortex was carried out as described, with minor modifications (Shi
et al., 2012a, 2012b). For drug treatment, all compounds were dissolved in
DMSO at the concentrations noted, and DMSO was the vehicle control in all
experiments. Compounds were added 30 min prior to incubation with recom-
binant tau protein (dynamin inhibitor Dynasore [Abcam] and actin polymeriza-
tion inhibitor Cytochalasin D [Tocris Bioscience]). To establish identity and
quality of neuronal induction, gene expression profiling was performed on a
custom gene expression panel. RNA was isolated from iPSC cortical induc-
tions, 35 days after induction, using an RNA extraction kit (QIAGEN), following
the manufacturer’s instructions. Expression of genes in neurons (MAP2,
MAPT, and NGN2), cerebral cortex progenitor cells (EMX2, PAX6, and
FOXG1), ventral telencephalon (NKX2-1 and LHX8), and mid-/hindbrain
(HOXA and HOXB) was assessed in all neuronal inductions on the Nanostring
nCounter platform. Cytotoxicity/cytolysis were assessed by analyzing the level
of lactate dehydrogenase (LDH) activity (Roche) in conditionedmedia samples
following treatments.
Recombinant Tau Expression and Purification
Tau P301S_103his-tag_avi-tag was overexpressed in BL21(DE3) bacteria.
Cells were lysed using BugBuster (Millipore), and clarified lysate was applied
to a 5-mL HisTrapHP column (GE Healthcare) in 23 PBS. Tau was eluted
using a 0- to 500-mM imidazole gradient. Peak fractions were pooled and
further purified in 23 PBS using a Superdex 200 16/60 gel filtration column
(GE Healthcare). Pooled fractions were then concentrated to approximately
8 mg/mL using a spin concentrator (Millipore). Final protein concentration
was determined by Nanodrop analysis.
Preparation of Tau Oligomeric Species
1 mL tau P301S at 8 mg/mL was incubated with 4 mg.mL1 heparin (Sigma)
in PBS plus 30 mM 3-(N-morpholino)propanesulfonic acid (MOPS) (pH 7.2)
at 37C for 72 hr. Aggregated material was diluted in 9 mL PBS plus
1% (v/v) sarkosyl (Sigma) and left rocking for 1 hr at room temperature to
completely solubilize any non-aggregated material. Insoluble tau was pelleted
by ultracentrifugation for 1 hr at 4C. The pellet was resuspended in 1 mL PBS
by vigorous pipetting and sonicated at 100 W for 33 20 s (Hielscher UP200St
ultrasonicator) to disperse clumps of protein and break large filaments into
smaller species.
Isolation of Internalized Recombinant Tau andWesternBlot Analysis
Whole-cell protein extraction was performed by lysis of cell pellets in cell
extraction buffer (Invitrogen) supplemented with PMSF (Sigma), protease in-
hibitors (Thermo Scientific), and phosphatase inhibitors (Thermo Scientific)
before collection of the soluble fraction by centrifugation at 10,000 3 g for
10 min. Soluble fractions were diluted in PBS and incubated with anti-FLAG
M2 Magnetic Beads (Sigma) overnight; magnetic beads with bound proteins
were washed following the manufacturer’s instructions and resuspended
in lithium dodecyl sulfate (LDS) PAGE loading buffer. Western blot analysis
was carried out using total tau antibody (Dako). Detection of immunoblot
was carried out using LI-COR Odyssey CLx Infrared Imaging System and
Image Studio Software.3622 Cell Reports 22, 3612–3624, March 27, 2018Labeling of Purified Recombinant Proteins
To label purified recombinant tau with Dylight 488 NHS ester (Thermo Fisher
Scientific), monomeric or aggregated tau P301S (concentration of 8 and
2 mg.mL1, respectively) was dialysed into PBS using Slide-A-Lyzer mini dial-
ysis units (Thermo Fisher Scientific) overnight at 4C. The dialysed tau prepa-
ration was then conjugated to 50 mg Dylight according to the manufacturer’s
protocol. Non-incorporated dye was removed by overnight dialysis against
23 1 L PBS at 4C and the concentration determined using a bicinchoninic
acid (BCA) protein quantification kit (Thermo Fisher Scientific).
To label purified recombinant tau with a pH-sensitive form of rhodamine
(pHrodo, Thermo Fisher Scientific), 150 mM tau protein (or equivalent protein
concentration for aggregate;7 mg.mL1) was incubated with 1.5 mM pHrodo
Red Maleimide (dissolved in DMSO) and 1.5 mM tris(2-carboxyethyl)phos-
phine) (TCEP) (1:10:10 molar ratio, respectively) for 2 hr in the dark at room
temperature (RT). After incubation, labeled protein samples were subjected
to size exclusion chromatography at 4C (Superdex 200 Increase 10/300 GL,
GE Healthcare) in 50 mM phosphate (pH 7.4) and 150 mM NaCl to remove un-
reacted dye and assess perturbation of oligomeric state by labeling (no change
was observed, data not shown). 10 mM 10-kDa dextran conjugated to pHrodo
(Thermo Fisher Scientific) was dissolved in DMSO. 5 mg. mL1 transferrin
conjugated to pHrodo (Thermo Fisher Scientific) was dissolved in PBS.
Analytical Size Exclusion Chromatography
Gel filtration chromatography used Superdex 200 increase 10/300 (GE
Healthcare). Protein samples (0.1–5 mg.mL1, 1% bed volume) were resolved
at a flow rate of 0.5 mL.min1; absorbance at 280 nm was monitored. Void
volume and specific molecular weights of globular calibration proteins were
determined using gel filtration low- and high-molecular weight calibration
kits (GE Healthcare).
Transmission Electron Microscopy
Formation of tau fibrils was confirmed by transmission electron microscopy,
largely as described (Goedert et al., 1992). Briefly, samples were mounted
on copper grids, stained with uranyl acetate, and negatively stained tau fibrils
were imaged as described (Goedert et al., 1992).
Labeled Tau Internalization Assays
Tau P301S labeled with either Dylight or pHrodo was diluted in neuronal
maintenance tissue culture medium and added to neurons at the
concentration and for the time indicated. Neurons were washed three times
using 13 Hank’s balanced salt solution (HBSS) before fixation and processing
for immunofluorescence and processing for flow cytometry or subjected to live
imaging.
Immunostaining, Confocal Microscopy, and Data Analysis
Immunohistochemistry was performed on neurons as previously described
(Shi et al., 2012a) using the following primary antibodies: MAP2 from Abcam
(ab5392), and EEA1 and LAMP1 from Cell Signaling Technology (C45B10
and D2D11). Secondary antibodies used were as follows: goat anti-mouse
Alexa594 (A21125), goat anti-chicken Alexa 647 (A21449), goat anti-rabbit
Alexa 546 (A11010), donkey anti-mouse Alexa 594 (A21203), and donkey
anti-rabbit Alexa 594 (A21207, all from Thermo Fisher Scientific). Images
were acquired using an Olympus FV1000 or Opera Phenix imaging systems.
Typically conditions were repeated in triplicate and >12 images were collected
per well. Quantification of fixed-cell imaging was performed using CellProfiler,
using an automated pipeline. The pipeline first detected nuclei using the DAPI
channel, their number, and the area was quantified. Next, the pipeline applied
a fixed-intensity threshold that was applied to every image in the 488/tau chan-
nel to exclude low-level detector noise, followed by 488 positive tau object
detection as primary objects andmeasuring of number and area. In co-labeling
experiments, endosomes labeledwith EEA1 or LAMP1 in the 546 channel were
analyzed as described above for the tau channel. Next, a mask was created
using the 546 channel. Application of this mask to the 488 channel allowed
measuring of the number and area of tau objects covered by the mask, i.e.,
the number of tau-positive vesicles (objects) that overlap with endosomal
markers EEA1 or LAMP1. To correct this measure for possible variations in
cell density in the image, it was normalized to the number of nuclei.
Flow Cytometry
After three 13 HBSS washes, neurons were dissociated using Accutase
(Sigma, A6964) into single cells. Dissociated cells were collected by low-speed
centrifugation (1,000 3 g for 1 min), the supernatant was removed, and cells
were fixed using 4% formaldehyde in PBS for 20 min at room temperature.
Cells were washed three times with PBS, nuclei counterstained with DAPI,
and analyzed using a BD LSRFortessa. Cells were gated using forward and
side scatter channels to remove debris and gated using the side scatter chan-
nel to remove doublets. Fluorescence in the DAPI and 466 channels of this
population was analyzed. Tau-negative neurons were defined using neurons
that had not been treatedwith tau (indicated in black in Figure 1B) and tau-pos-
itive neurons (indicated in green). Flow cytometry data were analyzed using
Flowing software.
Live Imaging and Data Analysis
Neurons grown on m-Plate 96 well (Ibidi) were imaged for fluorescent pHrodo-
labeled protein (excitation at 561 nm and emission at 570–630 nm) in an acidic
environment using a 403 confocal Opera Phenix high-content screening
system (PerkinElmer). Bright-field and fluorescence emission images were
collected at 10-min intervals. Parameters for fluorescent objects were set
(fluorescent intensity and contrast) and quantified using the Harmony software
(PerkinElmer). Data were analyzed using Prism Software (GraphPad). Typi-
cally, conditions were repeated at least in triplicate and <4 (typically 8) fields
were recorded per well. To track individual objects, images were collected
at 1-s intervals. Images were analyzed in Harmony 4.5 (PerkinElmer). Densely
clumped areas of wells were excluded, and a spot-finding algorithm was used
to detect foci of pHrodo-labeled protein. Within the spots, fluorescent intensity
of the Alexa-568 channel was quantified representing the amount of labeled
protein taken up into the endosomes. A high-intensity threshold was used
with the spot-finding algorithm to detect only the very bright spots within
the wells; discrete spots were counted to determine the number of pHrodo-
positive vesicles within the cells.
Statistical Analysis
The number of replica wells and experiments are indicated in the figure
legends for each assay where appropriate. For live-cell imaging assays using
pHrodo-labeled protein, intensity and number of objects were assessed
as described in Live Imaging and Data Analysis. Typically, 8 fields were re-
corded per well and an average generated from the Harmony 4.5 software
(PerkinElmer). Analyses were performed using the Prism version 7.0b software
(GraphPad). One-way ANOVA with Dunnett’s multiple testing or Student’s
t test was used where appropriate.
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